NLRP3 and chronic obstructive pulmonary disease: Since the inhibition of the SGLT-2 cotransporter modulates the NLRP3 inflammasome, at least in cardiovascular diseases associated with type 2 diabetes, it is suggested that this approach may also help to protect the heart from adverse pathological ventricular remodeling and cardiac arrhythmias, including postoperative atrial fibrillation, by suppressing inflammasome activity [Kim et al., 2020] [204].